Lucius Partners Portfolio Company AerWave Medical, Inc. Commences First-in-Human Trial of its Ultrasound Based Lung Denervation System for Treatment of COPD and Asthma

Friday, June 07, 2024

Lucius Partners, LLC, announced today that its subsidiary, AerWave Medical, has initiated its First-in-Human Trial (FIH) by treating the first two patients.

A renowned Interventional Pulmonologist, is leading the trial at Healthycor in Tbilisi, Georgia. A member of prestigious bronchology associations, lauded AerWave's balloon-based ultrasound platform for its simplicity and speed, highlighting its potential to revolutionize patient care.

The trial focuses on lung denervation to address Asthma and Chronic Obstructive Pulmonary Disease (COPD), with a novel approach developed by AerWave.

This innovative method aims to enhance efficacy while ensuring patient safety, as it targets tissue precisely without affecting surrounding nerves. With a projected enrollment of five patients, the trial aims to evaluate both safety and efficacy, building on extensive pre-clinical research.

The company's approach, emphasizing its potential to outperform existing treatments by providing complete coverage and avoiding common side effects associated with esophageal exposure.

Moreover, AerWave plans to extend its technology beyond lung denervation, exploring applications in lung tumor ablation (LTA) and lung volume reduction (LVR), where ultrasound offers distinct advantages over other modalities.

The significance of the FIH trial in demonstrating the platform's capabilities, which could broaden the scope of treatable conditions in respiratory medicine.

Collaborating with Prof. Tchkonia's team, the company aims to bolster its data sets, paving the way for future advancements in patient care.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USAHealthcare CFO, Financial Strategy & Revenue Cycle SummitHealthcare CEO & Executive Strategy Summit